Oral contraceptives with drospirenone increase risk of nonfatal DVT/PE (BMJ) - PulmCCM
Advertisement
Mar 182011
 

Drospirenone is the new progesterone analog in heavily marketed new oral contraceptive pills (trade names Yaz, Yasmin, Angelique). Using a large insurance claims database, Jick et al identified 186 cases of DVT or PE in women aged 15-44 taking oral contraceptives and compared them to controls. Those taking drospirenone-containing OCPs had a nonfatal DVT/PE incidence of 30 per 100,000 person-years, compared to 12.5 for those taking levonorgestrel-containing agents. BMJ 2011;342:d2151. FREE FULL TEXT

Liked this post? Get a weekly email update (no spam, ever), and explore our library of clinical guidelines, practice updatesreview articles. and board review questions.

PulmCCM is an independent publication, not affiliated with or endorsed by any other organization, society or journal referenced on the website.

Authors: contribute your work to PulmCCM Journal or in a guest blog post.

Leave a Comment